

Meningococcal Vaccines Ages 6 Weeks through 10 Years

<p>Age Indications for Each Brand</p> <p>MenHibrix® (Hib-MenCY): Ages 6 weeks through 18 months Menactra® (MCV4-D): Ages 2 months through 55 years MENVEO® (MCV4-CRM): Ages 9 months through 55 years</p> <p>Recommended Schedule</p> <ul style="list-style-type: none"> Vary by age and risk condition <p>Indication for Use</p> <ul style="list-style-type: none"> MenHibrix is recommended for infants at high risk for meningococcal disease and who also need a routine Hib vaccine; contains protection against serotypes C, Y Menactra and Menveo contain protection against serotypes A, C, W, Y <p>Minimum Interval</p> <ul style="list-style-type: none"> Varies by brand, risk group and age at time of vaccination 	<p>Vaccine Administration</p> <ul style="list-style-type: none"> Intramuscular (IM) injection in deltoid or anterolateral thigh <ul style="list-style-type: none"> 1-1.5 inch, 22-25 gauge needle Use professional judgment in selecting site and needle length Give simultaneously with all vaccines <p>Storage and Handling</p> <ul style="list-style-type: none"> Store in the refrigerator between 35°-46° F (2°-8° C) Stand-alone storage units are preferred Keep in the original box; Do Not freeze Menactra is ready to use; shake well <p>Reconstitute Menveo & MenHibrix</p> <ul style="list-style-type: none"> Menveo: draw up MenCYW liquid (diluent); add to Men A vial; invert; shake well MenHibrix: use saline diluent packaged with vaccine; draw up entire vial (0.85mL); Administer within 30 minutes
--	--



CHILDREN AGED 6 WEEKS THROUGH 10 YEARS WHO ARE AT INCREASED RISK FOR MENINGOCOCCAL DISEASE

- Children with anatomic or functional asplenia (including sickle cell disease):
 - For children younger than age 19 months, give a 4-dose series of MenHibrix or Menveo at age 2, 4, 6, & 12-15 months
 - For children age 19 through 23 months who have not completed a series of MenHibrix or Menveo, administer 2 primary doses of Menveo at least 3 months apart (doses valid if 8 weeks apart)
 - For children aged 24 months & older who have not received a complete series of MenHibrix, Menveo or Menactra, give 2 primary doses of either Menactra or Menveo at least 3 months apart (doses valid if 8 weeks apart)
 - Due to interference between the 2 vaccines, do not give Menactra prior to completing the Pneumococcal Conjugate Vaccine (PCV13) series; wait at least 4 weeks after the PCV13 series to give Menactra; Menveo can be given with PCV13
 - Booster dose for children: aged less than 7 years—in 3 years then every 5 years; aged 7 years or older—every 5 years
- Children with persistent complement component deficiency:
 - For children younger than age 19 months, give a 4-dose series of either MenHibrix or Menveo at age 2, 4, 6, & 12-15 months
 - For children aged 7 through 23 months who have not begun vaccination, 2 options exist depending on age & vaccine brand:
 - For children who began vaccination with Menveo at 7 months through 23 months of age, a 2-dose series should be administered with the second dose after 12 months of age and at least 3 months after the first dose.
 - For children who began vaccination with Menactra at 9 months through 23 months of age, a 2-dose series of Menactra should be administered at least 3 months apart (with at least 8 weeks between doses)
 - For children aged 24 months & older who have not received a complete series of MenHibrix, Menveo, or Menactra, administer 2 primary doses of either Menactra or Menveo at least 3 months apart¹(doses valid if 8 weeks apart)
 - Booster dose for children: aged less than 7 years- in 3 years then every 5 years; aged 7 years or older- every 5 years
- Children who travel to or reside in countries with high risk for meningococcal disease (i.e., African meningitis belt or the Hajj):
 - Administer age-appropriate dose(s) of Menactra or Menveo (contain serotypes A, W needed for travel)²
- Children at risk during a community outbreak due to serotype A, C, Y, or W-135
 - Administer or complete an age and formulation appropriate vaccine (refer to "Indications for Use")²

CONTRAINDICATIONS

- Menactra or Menveo: An anaphylactic (severe allergic) reaction to a prior dose or a component of meningococcal vaccine
- MenHibrix: An anaphylactic reaction to prior dose or component of meningococcal, Hib or tetanus-toxoid containing vaccines

PRECAUTIONS

- Moderate to severe acute illness with or without fever

FURTHER POINTS

- Meningococcal Vaccine Information Statement (VIS), can be found at <http://www.immunize.org/vis/>
- Use the lot number on the outside box of Menveo to document in GRITS and on the Vaccine Administration Record

¹Children indicated for a 2-dose primary series who previously received only 1 dose of MCV4, should get a 2nd dose of MCV4 as soon as feasible; forecast for the booster dose (if applicable) from the date of the 2nd primary dose

²Children aged 24 months & older with HIV and an indication for vaccination: if no previous complete series, give a 2-dose primary series (0, 2 month)

Resources: "Prevention and Control of Meningococcal Disease, Recommendations of the ACIP", March 22, 2013, located at www.cdc.gov/vaccines/recs.